Aileron Therapeutics, Inc. (NASDAQ:ALRN) Sees Significant Growth in Short Interest

Aileron Therapeutics, Inc. (NASDAQ:ALRN - Get Free Report) saw a significant growth in short interest in April. As of April 30th, there was short interest totalling 135,900 shares, a growth of 213.1% from the April 15th total of 43,400 shares. Based on an average trading volume of 85,700 shares, the short-interest ratio is currently 1.6 days. Currently, 1.0% of the shares of the stock are short sold.

Insider Activity at Aileron Therapeutics

In related news, major shareholder Of Texas/Texas Am I. University sold 10,746 shares of the firm's stock in a transaction on Monday, April 29th. The shares were sold at an average price of $4.95, for a total transaction of $53,192.70. Following the completion of the transaction, the insider now directly owns 1,799,711 shares of the company's stock, valued at $8,908,569.45. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Aileron Therapeutics news, major shareholder Of Texas/Texas Am I. University sold 20,315 shares of Aileron Therapeutics stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $4.21, for a total value of $85,526.15. Following the completion of the transaction, the insider now directly owns 1,779,306 shares of the company's stock, valued at approximately $7,490,878.26. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Of Texas/Texas Am I. University sold 10,746 shares of Aileron Therapeutics stock in a transaction on Monday, April 29th. The stock was sold at an average price of $4.95, for a total transaction of $53,192.70. Following the completion of the transaction, the insider now directly owns 1,799,711 shares of the company's stock, valued at $8,908,569.45. The disclosure for this sale can be found here. 5.57% of the stock is currently owned by corporate insiders.

Institutional Trading of Aileron Therapeutics

An institutional investor recently bought a new position in Aileron Therapeutics stock. Sigma Planning Corp purchased a new stake in Aileron Therapeutics, Inc. (NASDAQ:ALRN - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The firm purchased 16,580 shares of the company's stock, valued at approximately $51,000. Sigma Planning Corp owned approximately 0.34% of Aileron Therapeutics as of its most recent filing with the SEC. 90.89% of the stock is currently owned by institutional investors and hedge funds.

Aileron Therapeutics Trading Up 4.1 %

Shares of ALRN traded up $0.15 during trading hours on Friday, hitting $3.82. The company had a trading volume of 59,933 shares, compared to its average volume of 77,806. Aileron Therapeutics has a one year low of $1.01 and a one year high of $7.42. The company's fifty day moving average price is $5.30 and its two-hundred day moving average price is $3.91. The company has a market capitalization of $64.44 million, a PE ratio of -1.15 and a beta of 2.32.

Aileron Therapeutics (NASDAQ:ALRN - Get Free Report) last released its quarterly earnings results on Monday, April 15th. The company reported ($1.54) earnings per share for the quarter. Analysts forecast that Aileron Therapeutics will post -0.62 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, LADENBURG THALM/SH SH raised their price target on shares of Aileron Therapeutics from $9.00 to $19.00 and gave the stock a "buy" rating in a research note on Thursday, April 18th.

About Aileron Therapeutics

Aileron Therapeutics, Inc operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.